CRISPR Therapeutics AG: Q2 2024 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024, for CRISPR Therapeutics AG (CRSP), a leading gene editing company. The Company focuses on developing CRISPR/Cas9-based therapeutics, with its most advanced program, CASGEVY (exagamglogene autotemcel), approved for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. The Company operates in one segment: the discovery, development, and commercialization of genome-editing therapies.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $517 | $70,000 | $1,021 | $170,000 |
| Net Loss | $(126,408) | $(77,740) | $(242,999) | $(130,805) |
| Net Loss Per Share (Diluted) | $(1.49) | $(0.98) | $(2.92) | $(1.66) |
| Operating Expenses | $151,777 | $165,223 | $292,869 | $329,710 |
| Cash & Cash Equivalents | $484,472 | $444,796 | $484,472 | $444,796 |
| Marketable Securities | $1,528,363 | $1,306,188 | $1,528,363 | $1,306,188 |
| Total Liquidity (Cash + Securities) | $2,012,835 | $1,750,984 | $2,012,835 | $1,750,984 |
| Net Cash Provided by Operating Activities (YTD) | $14,170 | $(124,446) | $14,170 | $(124,446) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped significantly from $70.0 million in Q2 2023 to $0.5 million in Q2 2024. The prior year included a $70.0 million research milestone payment from Vertex Pharmaceuticals related to the diabetes collaboration, which did not recur in the current period.
- Increased Net Loss: Net loss widened to $126.4 million in Q2 2024 from $77.7 million in Q2 2023, primarily due to the absence of the non-recurring milestone revenue.
- Expense Reductions: Total operating expenses decreased by $13.4 million in Q2 2024 compared to the prior year. Research and Development (R&D) expenses fell by $21.4 million, driven largely by a $18.9 million decrease in external R&D costs. However, Collaboration Expense, net, increased by $7.5 million due to commercial and manufacturing costs for CASGEVY.
- Capital Raise: In February 2024, the Company completed a registered direct offering, raising approximately $279.0 million in net proceeds.
- Investment Income: Other income, net, increased to $26.1 million in Q2 2024 from $18.4 million in Q2 2023, driven by higher interest income on the Company's substantial cash and marketable securities portfolio.
Outlook, Risks, and Management Commentary
- Liquidity and Runway: Management expects existing cash, cash equivalents, and marketable securities ($2.0 billion as of June 30, 2024) to fund operating expenses and capital expenditures for at least the next 24 months, excluding potential proceeds from collaborations.
- CASGEVY Commercialization: The Company continues to advance CASGEVY, which has received approval in the U.S., EU, UK, Saudi Arabia, and Bahrain. Collaboration expenses are rising as the program moves into commercialization phases.
- Pipeline Progress: The Company is advancing multiple programs, including allogeneic CAR T candidates (CTX112, CTX131) for oncology and autoimmune diseases, and in vivo gene editing programs (CTX310, CTX320) for cardiovascular disease.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to achieve profitability, dependence on collaborations (specifically Vertex), and the need for additional capital to fund long-term development. The Company maintains a valuation allowance against certain deferred tax assets.
- Contingencies: The Company has deferred costs related to the CASGEVY program under the amended Joint Development and Commercialization Agreement (A&R Vertex JDCA). As of June 30, 2024, $4.0 million of 2024 costs have been deferred, with no contingent payments accrued to date.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for future milestone payments from Vertex and the potential for product sales revenue from CASGEVY, given the current lack of product revenue.
- Burn Rate vs. Cash Runway: Confirm the 24-month liquidity runway estimate against current quarterly burn rates and potential increases in commercialization costs.
- CASGEVY Cost Sharing: Review the specific terms of the A&R Vertex JDCA regarding cost deferrals and the 40/60 profit-sharing split to understand future cash flow implications.
- Investment Portfolio: Assess the unrealized losses on marketable securities ($2.9 million net unrealized loss as of June 30, 2024) and the impact of interest rate changes on the portfolio's fair value.
- Intellectual Property: Monitor ongoing litigation and administrative proceedings related to the Company's intellectual property estate, as noted in the Risk Factors.